Skip to main content

Page last checked

Goal

Peptides for skin

The evidence for skin benefits depends on the route. Studies of creams or wound treatments do not show a dose for a skin-care injection.

Source for this answer

Source: Based on 3 compound guides · checked 2026-09-07

Source: Based on 3 compound guides · checked 2026-09-07

GHK-Cu, KPV and LL-37 have different kinds of skin evidence. The studies used different products for different conditions, so results cannot be applied to every product carrying the same name.

For cosmetic ingredients in creams and serums, see the separate skincare guide. Here, the comparison keeps those topical findings distinct from claims about injections.

At a glance

Compounds covered

3

FDA-approved for this goal

0

Being tested for this goal

0

Reported use only

2

Three compounds, and what was tested on skin

Each row names the product and the skin problem tested. A finding about a cream, an ulcer or an animal experiment has limits in other settings.

◆ 3 compounds coveredsources shown in each row
Compounds people take for this purpose, why they use them, what human research has measured, and where the evidence comes from.
CompoundWhat people take it forWhat research showsEvidence
GHK-CuSold for wrinkles, firmness, scars and hair regrowth, in both topical and injectable products.Reported use onlyTopical studies concern specific skin conditions. A small study after laser treatment found no significant improvement over the control in blinded skin assessments, although patients reported greater satisfaction. These findings do not show an injection dose.indirect evidenceNo human dose published
KPVSold for eczema and other inflamed skin, and for gut inflammation alongside it.Reported use onlyTests in cells and in mice with colitis found changes in signals linked to inflammation. FDA reports that it has not identified human exposure data for KPV by any route. These findings do not show a human skin treatment.no human dose shown to workNo human dose published
LL-37Sold for stubborn skin infections and biofilms, on its natural role in the skin’s own defenses.Measured in a human studyThe human work cited here includes topical ulcer treatment and injections into melanoma deposits. On venous leg ulcers the two lower strengths improved healing while the highest did no better than placebo. FDA cited animal findings of harm to male reproduction and of tumor-promoting activity in some tissues.limited human dataDose from a human trial · no FDA label

1 rests on a human study that measured something in this goal. 2 rest on reported use alone, with no study behind them.

A cosmetic ingredient is not an approved injectable treatment

GHK-Cu is used in cosmetics under the name copper tripeptide-1. Its presence in a cream does not show that injecting it improves skin or is safe.

FDA’s entry specifically identifies limited human data and potential risks for injectable GHK-Cu. The route matters when interpreting both the cosmetic literature and the regulator’s concerns.

No established dose for a skin-care injection

The studies do not set an injected dose for wrinkles, firmness or general skin health. LL-37 studies used preparations for venous ulcers or injections into melanoma deposits, which are different settings.

FDA reports that it has not identified human exposure data for KPV. An unsuccessful search for data is different from a trial finding no benefit.

Where to go next

Peptide serums: the result belongs to the formula

A named ingredient is not evidence that every product containing it performs alike.

Every purpose, and what backs each one

10 purposes and 50 compound-and-purpose pairings, of which 23 rest on reported use alone.

The testosterone table, basis by basis

Compare why people use each compound with what human studies have actually measured for testosterone.

Weight loss: the page beside the pitch

Approval, a positive trial and a product are three different things.

What KPV is, how it is used, and what has been studied

KPV is an alpha-msh c-terminal tripeptide (research compound).

LL-37 research, dosing, and approval status

No regulator has approved LL-37; the guide separates human studies from reported use.

How GHK-Cu differs from the rest of its class

No published human dosing schedule was found for GHK-Cu.

Healing and recovery: the page beside the pitch

The compound and the injury both matter.

Every purpose covered this way is listed on the index of goals people buy peptides for.

15primary sources, each with the day we read it — open the documents used on this page